Covalent Single-Domain Antibodies for Botulinum Toxin Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for botulism caused by botulinum neurotoxins, particularly those targeting light chain A (LC/A), lack effective and specific antidotes that can inhibit toxicity with high potency and specificity.
Innovation Solution
Development of single-domain antibodies (sdAbs) comprising reactive non-canonical amino acids (ncAAs) that can form covalent bonds with Botulinum neurotoxin light chain A (LC/A), enabling irreversible binding and neutralization of the toxin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies or reagents are used to target Botulinum neurotoxin LC/A, then general binding may be achieved, but high potency and specificity to inhibit toxicity is not attained
Solution Approach 1:
The patent introduces reactive non-canonical amino acids (ncAAs) at specific local positions within the sdAb structure. These ncAAs are incorporated at defined sites (e.g., through genetic code expansion) to create localized reactive centers that covalently bind to LC/A, while the rest of the sdAb maintains its native binding specificity. This local modification approach achieves high potency and specificity without requiring complete redesign of the entire antibody molecule.
Solution Approach 2:
The patent changes the chemical parameters of the antibody by incorporating non-canonical amino acids with reactive functional groups (e.g., photoreactive or spontaneously reactive groups). This parameter change transforms the binding mechanism from non-covalent to covalent, dramatically increasing the potency and irreversibility of LC/A inhibition while maintaining the ability to control the reaction through parameters like light exposure or pH.
2Reliability
If reactive non-canonical amino acids are incorporated into sdAbs, then covalent binding and irreversible inhibition of LC/A is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent employs systems where the reactive ncAAs are incorporated through self-organizing mechanisms. For example, genetic code expansion systems use orthogonal tRNA/synthetase pairs that automatically incorporate the desired ncAA at the specified codon position during expression. Alternatively, spontaneous crosslinking ncAAs react automatically under physiological conditions without requiring external activation, making the manufacturing process simpler despite the chemical complexity of the ncAAs themselves.
Solution Approach 2:
The patent performs preliminary incorporation of reactive ncAAs into the sdAb during the expression stage, before the final purification and application steps. This preliminary action ensures that the reactive groups are already in place and properly positioned, eliminating the need for complex post-translational modification steps and simplifying the overall manufacturing workflow.
3Reliability
If sdAbs with reactive ncAAs are used, then enhanced potency and specificity against LC/A is achieved, but potential off-target reactivity may increase
Solution Approach 1:
The reactive ncAA is placed at a specific local position within the sdAb that is strategically positioned to be close to the LC/A binding interface. This local placement ensures that the reactive group is spatially constrained to react primarily with LC/A when bound, reducing the probability of off-target reactions with unrelated proteins. The rest of the sdAb structure maintains its high specificity for LC/A, providing a second layer of selectivity.
Solution Approach 2:
The sdAb is designed to bind to LC/A with high affinity and specificity before the covalent reaction occurs. This preliminary high-affinity binding acts as a filter, ensuring that only the correct target (LC/A) is positioned close enough to the reactive ncAA for covalent reaction to occur. This pre-binding step prevents off-target proteins from accessing the reactive group, thereby reducing harmful off-target effects while maintaining high potency against the intended target.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ncAA-substituted sdAbs demonstrate enhanced target specificity and potency in inhibiting Botulinum neurotoxin LC/A, offering a promising therapeutic approach for treating botulism with reduced off-target effects.
Implementation Method 1
the ncAA incorporated in the sdAb is 4-azidophenylalanine (AzF), which forms covalent bonds with nearby groups on a target antigen protein following photoillumination, e.g., UV radiation
Implementation Method 2
the ncAA incorporated in the sdAb is O-(2-bromoethyl)tyrosine (OBeY), which is spontaneously reactive and forms covalent bonds with nearby groups on a target antigen protein
Data Source
AI summary
Provided are single-domain antibodies (sdAbs), also called heavy-chain-only variable domains (VHHs) or camelids, that contain reactive, non-canonical amino acids (ncAAs) and crosslink to target antigen protein. The target antigen may be a toxin or a neurotoxin produced by a pathogenic organism or microorganism that causes or is associated with a disease or pathology. Compositions and methods using the reactive ncAA-containing sdAbs to treat subjects afflicted with a pathology caused by a toxin- or neurotoxin-producing pathogen, such as Botulinum, are provided. In some cases, the compositions and methods comprising the sdAbs treat or prevent intoxication and inhibit and/or neutralize toxin or neurotoxin activity.